dc.contributor.author | Shu SH | |
dc.contributor.author | Magnussen CG | |
dc.contributor.author | Hu JC | |
dc.contributor.author | Hu SS | |
dc.contributor.author | Wang D | |
dc.contributor.author | Xie LX | |
dc.contributor.author | Chai XQ | |
dc.date.accessioned | 2022-10-28T14:26:06Z | |
dc.date.available | 2022-10-28T14:26:06Z | |
dc.identifier.uri | https://www.utupub.fi/handle/10024/171342 | |
dc.description.abstract | Objectives: This study aimed to determine the effect of intraoperative administration of flurbiprofen on postoperative levels of programmed death 1 (PD-1) in patients undergoing thoracoscopic surgery. Materials and Methods: In this prospective double-blind trial, patients were randomized to receive intralipid (control group, n = 34, 0.1 mL/kg, i.v.) or flurbiprofen axetil (flurbiprofen group, n = 34, 50 mg, i.v.) before induction of anesthesia. PD-1 levels on T cell subsets, inflammation, and immune markers in peripheral blood were examined before the induction of anesthesia (T-0) and 24 h (T-1), 72 h (T-2), and 1 week (T-3) after surgery. A linear mixed model was used to determine whether the changes from baseline values (T-0) between groups were significantly different. Results: The increases in the percentage of PD-1((+))CD8((+)) T cells observed at T-1 and T-2 in the control group were higher than those in the flurbiprofen group (T-1: 12.91 +/- 1.65 vs. 7.86 +/- 5.71%, p = 0.031; T-2: 11.54 +/- 1.54 vs. 8.75 +/- 1.73%, p = 0.004), whereas no differences were observed in the changes in the percentage of PD-1((+))CD4((+)) T cells at T-1 and T-2 between the groups. Moreover, extensive changes in the percentage of lymphocyte subsets and inflammatory marker concentrations were observed at T-1 and T-2 after surgery and flurbiprofen attenuated most of these changes. Conclusions: Perioperative administration of flurbiprofen attenuated the postoperative increase in PD-1 levels on CD8((+)) T cells up to 72 h after surgery, but not after this duration. The clinical relevance of changes in PD-1 levels to long-term surgical outcome remains unknown. | |
dc.language.iso | en | |
dc.publisher | KARGER | |
dc.title | Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer | |
dc.identifier.url | https://www.karger.com/Article/FullText/503166 | |
dc.identifier.urn | URN:NBN:fi-fe2021042826548 | |
dc.relation.volume | 29 | |
dc.contributor.organization | fi=sydäntutkimuskeskus|en=Research Centre of Applied and Preventive Cardiovascular Medicine (CAPC)| | |
dc.contributor.organization-code | 2607004 | |
dc.converis.publication-id | 46658808 | |
dc.converis.url | https://research.utu.fi/converis/portal/Publication/46658808 | |
dc.format.pagerange | 159 | |
dc.format.pagerange | 150 | |
dc.identifier.jour-issn | 1011-7571 | |
dc.okm.affiliatedauthor | Magnussen, Costan | |
dc.okm.discipline | 3122 Syöpätaudit | fi_FI |
dc.okm.discipline | 3122 Cancers | en_GB |
dc.okm.internationalcopublication | international co-publication | |
dc.okm.internationality | International publication | |
dc.okm.type | Journal article | |
dc.publisher.country | Sveitsi | fi_FI |
dc.publisher.country | Switzerland | en_GB |
dc.publisher.country-code | CH | |
dc.relation.doi | 10.1159/000503166 | |
dc.relation.ispartofjournal | Medical Principles and Practice | |
dc.relation.issue | 2 | |
dc.year.issued | 2020 | |